In a report released today, Jonathan Demchick from Morgan Stanley maintained a Hold rating on NuVasive (NASDAQ: NUVA), with a price target of $77. The company’s shares closed yesterday at $68.40, close to its 52-week high of $72.12.
According to TipRanks.com, Demchick is ranked #1849 out of 4877 analysts.
Currently, the analyst consensus on NuVasive is a Moderate Buy with an average price target of $69.20.
See today’s analyst top recommended stocks >>
The company has a one-year high of $72.12 and a one-year low of $44.62. Currently, NuVasive has an average volume of 599.7K.
TipRanks has tracked 36,000 company insiders and found that a few of them are better than others when it comes to timing their transactions. See which 3 stocks are most likely to make moves following their insider activities.
NuVasive, Inc. engages in the development of minimally-disruptive surgical products and procedurally-integrated solutions for spine surgery. It offers cervical and spine fusion surgery, cervical plating, and posterior fixation products. The company was founded by Alexis V. Lukianov on July 21, 1997 and is headquartered in San Diego, CA.
